Literature DB >> 19662365

Lipopolysaccharide "two-hit" induced refractory hypoxemia acute respiratory distress model in rats.

Yumei Li1, Hongchang Wei.   

Abstract

To establish a stable and reliable model of refractory hypoxemia acute respiratory distress syndrome (ARDS) and examine its pathological mechanisms, a total of 144 healthy male Wistar rats were randomized into 4 groups: group I (saline control group), group II (LPS intravenous "single-hit" group), group III (LPS intratracheal "single-hit" group) and Group IV (LPS "two-hit" group). Rats were intravenously injected or intratracheally instilled with a large dose of LPS (10 mg/kg in 0.5 mL) to simulate a single attack of ARDS, or intraperitoneally injected with a small dose of LPS (1 mg/kg) followed by tracheal instillation with median dose of LPS (5 mg/kg) to establish a "two-hit" model. Rats in each group were monitored by arterial blood gas analysis and visual inspection for three consecutive days. Arterial blood gas values, lung wet/dry weight ratio and pathological pulmonary changes were analyzed to determine the effects of each ALI/ARDS model. Concentrations of TNF-alpha, IL-1 and IL-10 in the bronchoalveolar lavage fluid (BALF) and blood plasma were measured by using enzyme-linked immunosorbent assays (ELISA). Our results showed that single LPS-stimulation, whether through intravenous injection or tracheal instillation, could only induce ALI and temporary hypoxemia in rats. A two-hit LPS stimulation induces prolonged hypoxemia and specific pulmonary injury in rats, and is therefore a more ideal approximation of ARDS in the animal model. The pathogenesis of LPS two-hit-induced ARDS is associated with an uncontrolled systemic inflammatory response and inflammatory injury. It is concluded that the rat ARDS model produced by our LPS two-hit method is more stable and reliable than previous models, and closer to the diagnostic criteria of ARDS, and better mimics the pathological process of ARDS.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19662365     DOI: 10.1007/s11596-009-0416-6

Source DB:  PubMed          Journal:  J Huazhong Univ Sci Technolog Med Sci        ISSN: 1672-0733


  18 in total

1.  Intratracheal aerosolization of endotoxin (LPS) in the rat: a comprehensive animal model to study adult (acute) respiratory distress syndrome.

Authors:  H P van Helden; W C Kuijpers; D Steenvoorden; C Go; P L Bruijnzeel; M van Eijk; H P Haagsman
Journal:  Exp Lung Res       Date:  1997 Jul-Aug       Impact factor: 2.459

2.  Development of animal models for the acute respiratory distress syndrome.

Authors:  Julie A Bastarache; Timothy S Blackwell
Journal:  Dis Model Mech       Date:  2009 May-Jun       Impact factor: 5.758

3.  In vivo lipid-derived free radical formation by NADPH oxidase in acute lung injury induced by lipopolysaccharide: a model for ARDS.

Authors:  Keizo Sato; Maria B Kadiiska; Andrew J Ghio; Jean Corbett; Yang C Fann; Steven M Holland; Ronald G Thurman; Ronald P Mason
Journal:  FASEB J       Date:  2002-11       Impact factor: 5.191

4.  A comparison among animal models of acute lung injury.

Authors:  C Rosenthal; C Caronia; C Quinn; N Lugo; M Sagy
Journal:  Crit Care Med       Date:  1998-05       Impact factor: 7.598

5.  Sigh in acute respiratory distress syndrome.

Authors:  P Pelosi; P Cadringher; N Bottino; M Panigada; F Carrieri; E Riva; A Lissoni; L Gattinoni
Journal:  Am J Respir Crit Care Med       Date:  1999-03       Impact factor: 21.405

6.  Blunted inflammatory response to lipopolysaccharide endotracheal instillation due to thermal preconditioning.

Authors:  A Di Filippo; S Rinaldi; C Pascente; D Messeri; A R De Gaudio
Journal:  Minerva Anestesiol       Date:  2005-10       Impact factor: 3.051

Review 7.  Future research directions in acute lung injury: summary of a National Heart, Lung, and Blood Institute working group.

Authors:  Michael A Matthay; Guy A Zimmerman; Charles Esmon; Jahar Bhattacharya; Barry Coller; Claire M Doerschuk; Joanna Floros; Michael A Gimbrone; Eric Hoffman; Rolf D Hubmayr; Mark Leppert; Sadis Matalon; Robert Munford; Polly Parsons; Arthur S Slutsky; Kevin J Tracey; Peter Ward; Dorothy B Gail; Andrea L Harabin
Journal:  Am J Respir Crit Care Med       Date:  2003-04-01       Impact factor: 21.405

8.  Nebulized prostacyclin (PGI2) in acute respiratory distress syndrome: impact of primary (pulmonary injury) and secondary (extrapulmonary injury) disease on gas exchange response.

Authors:  G Domenighetti; H Stricker; B Waldispuehl
Journal:  Crit Care Med       Date:  2001-01       Impact factor: 7.598

Review 9.  Overview of the pathology of three widely used animal models of acute lung injury.

Authors:  H M Wang; M Bodenstein; K Markstaller
Journal:  Eur Surg Res       Date:  2008-03-19       Impact factor: 1.745

10.  Neutrophil elastase and systemic inflammatory response syndrome in the initiation and development of acute lung injury among critically ill patients.

Authors:  Seitaro Fujishima; Hiroshi Morisaki; Akitoshi Ishizaka; Yoshifumi Kotake; Masaru Miyaki; Kikuo Yoh; Kazuhiko Sekine; Junichi Sasaki; Sadatomo Tasaka; Naoki Hasegawa; Yohko Kawai; Junzo Takeda; Naoki Aikawa
Journal:  Biomed Pharmacother       Date:  2007-07-31       Impact factor: 6.529

View more
  3 in total

1.  A modified "double-hit" induced acute lung injury model in rats and protective effects of tetramethylpyrazine on the injury via Rho/ROCK pathway.

Authors:  Shidi Zhao; Yong Zhang; Qianfen Chen; Shuying Dong; Gaofeng Zhang; Jia Li; Xilan Yang; Yan Li
Journal:  Int J Clin Exp Pathol       Date:  2015-05-01

2.  Dual hit lipopolysaccharide & oleic acid combination induced rat model of acute lung injury/acute respiratory distress syndrome.

Authors:  T N Hagawane; R V Gaikwad; N A Kshirsagar
Journal:  Indian J Med Res       Date:  2016-05       Impact factor: 2.375

3.  Acupoint Catgut Embedding Improves the Lipopolysaccharide-Induced Acute Respiratory Distress Syndrome in Rats.

Authors:  Dan Li; Tian Sun; Laiting Chi; Dengming Zhao; Wenzhi Li
Journal:  Biomed Res Int       Date:  2020-05-02       Impact factor: 3.411

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.